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Abstract: Scleroderma is a highly complex disorder in its clinical
manifestations and pathogenesis. It has a wide range of clinical manifes-
tations due to varying degrees of vasculopathy, autoimmunity, altered
endothelium function, and abnormal fibrosis. The most widely used
classification system grouped eosinophilic fasciitis and disabling pan-
sclerotic morphea of childhood into the category of deep morphea. This
previous classification does not include a category for overlapping
conditions. A proposed new classification includes a new mixed subtype
in which a combination of two or more of the previous subtypes is present
in the same individual, although eosinophilic fasciitis has been excluded.
We present the case of a 4-year-old boy who presented with features of
disabling pansclerotic morphea and eosinophilic fasciitis simultaneously,
which to our knowledge has not been previously reported. This suggests
that these diseases are part of a more closely related continuum rather
than separate disorders, as currently classified.
Scleroderma is a rare spectrum of ﬁbrosing disor-
ders ranging from localized scleroderma (morphea) to
systemic sclerosis. Within the most widely used
classiﬁcation of localized scleroderma, deep morphea
encompasses morphea profundus, eosinophilic fasci-
itis (EF), and disabling pansclerotic morphea of
children (DPM) (1,2). Typically, deep morphea ex-
tends from the deep dermis to muscle in a diﬀuse
pattern, separating it from other forms of morphea
(3). Each of these conditions has similarities in clinical
presentation and laboratory and histologic ﬁndings,
but they have diﬀerent degrees of cutaneous involve-
ment and response to treatment (3,4). Previous case
reports have postulated a possible relationship
between these subtypes of morphea because of simul-
taneous presentations in individual patients (3,4). A
new classiﬁcation for juvenile localized scleroderma
has been recently proposed to include ﬁve subtypes:
circumscribed morphea, linear scleroderma, general-
ized morphea, pansclerotic morphea, and a mixed
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subtype (5). This new mixed subtype includes diﬀerent
types of lesions occurring in the same individual but
intentionally excludes eosinophilic fasciitis. A recent
multicenter study reported that this mixed subtype is
more common than previously recognized, account-
ing for 15% of the whole group (6). Balat et al (7)
reported a child with EF who progressed to linear
scleroderma. Farrington et al (8) reported four pedi-
atric patients who progressed from EF to localized
scleroderma. He suggested that two-thirds of pediatric
patients with EF progress to some form of sclero-
derma with cutaneous ﬁbrosis (7,8). We report a 4-
year-old with DPM and concurrent presentation of
EF disease features, suggesting that these two entities
may be related.
CASE REPORT
A previously healthy 4-year-old Caucasian boy pre-
sented with a 5-month history of progressive skin
discoloration and thickening on his trunk and
extremities. He had severe fatigue, generalized mal-
aise, arthralgia, myalgia, decreased appetite, weight
loss, and abdominal distention. On examination, the
patient appeared ill, with periorbital swelling, oral and
groin erosions, and massive matted, nontender cervi-
cal and inguinal lymphadenopathy. He had hypopig-
mented patches on the neck and trunk and atrophic,
waxy-textured, bound-down, erythematous to yellow
plaques on his chest, abdomen, and lower extremities.
Joint examination revealed nontender swelling of the
proximal interphalangeal joints, wrists, and knees,
with ﬁxed contractures of all peripheral joints. Digital
tapering and pallor was noted (Figs. 1–3).
Extensive examination for malignancy (including
imaging and bone marrow and lymph node biopsies)
and infection was negative. He had high inﬂammatory
markers, leukocytosis, eosinophilia (white blood cell
[WBC] count of 6,800 and 11,000), and anemia. Liver
and muscle enzymes were normal, with no evidence of
internal organ involvement. At diagnosis, antinuclear
antibody (ANA) titer was 1:160, but all other autoanti-
bodies were negative, including anti-Smith antibody,
anti-SSA antibody, anti-SSB antibody, anti-ribonu-
cleoprotein antibody, anti-double-stranded deoxyri-
bonucleic acid antibody, anti-SCL-70 antibody,
anticentromere antibody, and anti-Jo1 antibody.
We performed a wedge biopsy that included tissue
layers from the epidermis to muscle. The histopatho-
logic evaluation revealed thinning of the epidermis
and ﬂattening of undulations between the rete ridges
and dermal papillae. There were fewer subcutaneous
adnexa and vessels, which were widely separated from
each other. The dermis and underlying fascia were
thick, with extensive deposition of collagen ﬁbers
inﬁltrated by extensive inﬂammatory inﬁltrate com-
Figure 1. Hypopigmented patches on the neck and trunk
and atrophic plaques on the chest, abdomen, and upper
extremities.
Figure 2. Hyperpigmented sclerotic plaques on the back.
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posed of mononuclear inﬂammatory cells, plasma
cells, lymphocytes, histiocytes, and abundant eosin-
ophils. The inﬂammatory inﬁltrate extended into and
in between the underlying muscle ﬁbers, focally
surrounding fragmented myocytes (myocytes necro-
sis; Fig. 4), consistent with DPM and EF with
associated myopathy.
The patient was initially treated with intravenous
(IV) methylprednisolone and IV immunoglobulin
(IVIG). Outpatient therapy included daily oral ste-
roids, weekly subcutaneous methotrexate, and
monthly IVIG and IV methylprednisolone. Over the
next 2 years the patient had slow but gradual
improvement in his skin and joint range of motion
on combination immune modulation with predniso-
lone, methotrexate, mycophenolate mofetil, imatinib,
and monthly IVIG. Increased disease activity was
always marked by worsening peripheral eosinophilia
and increased erythrocyte sedimentation rate, both of
which responded robustly to increased steroid ther-
apy. More recently, the disease recurred, and autol-
ogous stem cell transplantation was performed.
Although the patient tolerated stem cell transplant
without serious complications, his disease relapsed
Figure 3. Inflammatory changes with periorbital swelling
and hypopigmented and hyperpigmented patches on the
face.
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Figure 4. Histopathologic evaluation of the skin, fascia, and muscle: (A) full-thickness skin, panniculus adiposus, and
fascia biopsy; (B) thinning of the epidermis and significantly widened dermis with extensive deposition of collagen fibers
parallel to the surface and a decrease in the number of cutaneous adnexa units and blood vessels; (C and D) the septa of
panniculus adiposus and thickened fascia involvement by mixed inflammatory cell infiltrate composed of lymphocytes,
plasma cells and eosinophils, and focal necrobiosis (arrow); (E) perivascular inflammatory infiltrates; (F) fascia with
inflammatory infiltrate extension into and in between the underlying muscle fibers; and (G) focal myocytes necrosis.
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with peripheral eosinophilia and new skin lesions on
his abdomen within 3 months after transplantation
while taking no immunosuppressive medications. His
disease has stabilized on systemic steroids, and he is
currently receiving abatacept infusions in an attempt
to mitigate steroid exposure.
DISCUSSION
Shulman ﬁrst described a new sclerodermatous
syndrome with diﬀuse fasciitis, hypergammaglobulin-
emia, and peripheral eosinophilia (9), which Rodnan
et al (10) later named “eosinophilic fasciitis.” Bielsa
et al (3) stated that Dıaz-Perez et al ﬁrst reported
children with a mutilating form of cutaneous sclero-
derma and named it DPM. Peterson et al (1)
grouped EF and DPM under deep morphea. These
two types of deep morphea diﬀer in the depth of the
disease.
These diseases are rare in children, with only 53 EF
cases and 24 DPM cases previously reported. Eosin-
ophilic fasciitis has been reported in combination with
linear or localized morphea (3) and with features of
scleredema adultorum in two cases (11,12). This case
highlights a pediatric patient with concurrent DPM
and EF.
Disabling pansclerotic morphea is rapidly progress-
ing pansclerosis extending to all the layers of the skin
from the dermis to the subcutaneous tissue, fascia,
muscle, and bone (13). It is an aggressive mutilating
form of deep morphea, reported most commonly in
girls ages 1 to 14 years old, although adult onset has
been reported (3,14). DPM initially begins on the
extremities and spreads to the trunk, scalp, and face,
resulting in contractures and atrophy (3).
Disabling pansclerotic morphea typically presents
with sclerotic plaques on the extensor surface and
trunk, which can progress to the entire skin. The
sclerotic lesions are usually superﬁcial and ill deﬁned
and appear bound to the underlying fascia (13,15).
Joint contractures, nonhealing ulcers, and soft tissue
calciﬁcations are common; ﬁngertip and toe involve-
ment is rare (3,13).
Hypergammaglobulinemia is a common ﬁnding,
although hypogammaglobulinemia has been reported
(13). Mild peripheral eosinophilia, high inﬂammatory
markers, and an intermittent positive ANA are
typically seen (3), although eosinophilia as a biomar-
ker of disease activity has not been previously
reported in DPM. Visceral involvement in DPM can
include lymph nodes, lungs, muscles, and esophagus,
and in rare cases, hepatic and cardiac involvement
have been reported (3,13,16). Pulmonary function
tests, electromyography, and barium swallow are
often abnormal (3). Zulian et al (17) stated that
patients with localized scleroderma with extracutane-
ous manifestations represent a new subset of patients
with mild, non-life-threatening organ involvement,
suggesting that localized scleroderma and systemic
sclerosis represent the ends of a continuous disease
spectrum.
Histologic changes depend on the depth of skin
involvement. In DPM, diﬀuse inﬂammation of the
entire dermis and panniculus is noted, including
lymphocytes, plasma cells, and eosinophils. This
progresses to sclerosis and thickening aﬀecting the
entire dermis and panniculus (3).
Disabling pansclerotic morphea is a disabling dis-
ease and has a poor prognosis, with severe orthopedic,
cosmetic, and psychological complications (1). Dis-
abling panscleroticmorphea has a chronic, progressive
disease course and is often refractory to treatment (3).
Some success has occurred with a combination of
steroids and immunosuppressive agents.
In contrast, EF mostly aﬀects the fascia and
panniculus and may aﬀect the dermis and muscle. It
is rare in children, aﬀecting girls more than boys (9). It
is a rapidly spreading disease that occurs in the
extremities, trunk, and neck, sparing the hands and
face. The etiology of deep morphea is unknown but is
postulated to be multifactorial, involving genetic and
environmental factors (1,3). The process initially
involves an inﬂammatory stage followed by excess
accumulation of collagen and dermal ﬁbrosis (3).
Early manifestations of EF involve symmetric diﬀuse
tenderness, warmth, and stiﬀness of the extremities. It
is often associated with erythema, early induration,
edema, alopecia, and scaling of the skin. Pitting
edema, dimpling of the skin (cobblestoning or peau
d’orange), and furrows along superﬁcial veins develop
as the disease progresses (1,3,9,18,19). With increasing
ﬁbrosis, the skin becomes hypopigmented, appears
tight and indurated, and is often tender (3). Joint
contractures, inﬂammatory arthritis, carpal tunnel,
and constitutional symptoms are common. Ray-
naud’s phenomenon and nail capillary involvements
are rare (20). Underlying skeletal muscle can be
aﬀected (9).
Findings in EF include hypergammaglobulinemia,
high peripheral eosinophilia, and high inﬂammatory
markers and muscle enzymes (creatine phosphoki-
nase, aldolase). A positive ANA is rare. It can be
associated with hematologic disorders, including
cytopenia (9). It is uncommon for EF to have visceral
involvement (4), although some reports have
stated that EF may be seen with mild lung, muscle,
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esophageal, hepatosplenic, and cardiac abnormalities
(3,20).
The criterion standard for diagnosing EF requires
a wedge biopsy including skin, muscle, and fascia
(1,9). With EF, early changes are seen in interlobular
ﬁbrous septa of the subcutis and deep fascia with
edema and inﬁltration of lymphocytes, histiocytes,
plasma cells, and eosinophils (3,10). Eventually it
progresses to diﬀuse inﬂammation in the fascia and
subcutis with eosinophilia and thickening and sclero-
sis of the dermis extending into the underlying muscle
(3,9), although the presence of eosinophils is not
necessary to make the diagnosis (13).
Eosinophilic fasciitis usually has a good outcome,
especially with early diagnosis and treatment (8); poor
prognosis is associated with young age of onset,
truncal involvement, and morphea lesions (9). Far-
rington et al (8) found risk factors for progression to
include age younger than 7 years and extensive disease
at time of diagnosis. Unlike DPM, EF is often
responsive to corticosteroids, immunosuppressive
agents (methotrexate, mycophenolate), and biological
agents (inﬂiximab) (9).
Our patient presented with severe disease with
features of DPM and EF at a very young age. He had
constitutional symptoms, joint contractures, lymph-
adenopathy, sclerotic skin changes with hypopigmen-
tation, erythema, edema, and ulceration. He had
sclerodactyly but no Raynaud’s phenomenon. His
gamma globulin, liver, and muscle enzyme levels were
within normal limits. He had a positive ANA, high
inﬂammatory markers, leukocytosis, and anemia. He
had no visceral involvement other than lymphadenop-
athy. All of these features can be seen in DPM.He had
other ﬁndings indicating EF, including high peripheral
eosinophilia and changes in his eosinophil count that
corresponded directly with disease activity. In a review
of the literature, six cases did not report the level of
eosinophilia, nine cases reported eosinophilia but did
not specify levels, two cases reported high eosinophilia
(30%with 13,000WBC count and 9.5%with noWBC
count provided), and the remaining seven cases of
childhood DPM had normal to mild peripheral eosin-
ophil counts (13,14,16,21). All EF cases had high
eosinophil counts. Histologic ﬁndings in our patient
also showed abundant eosinophils and thickened
fascia. In a review of the literature, only one of the
DPM cases mentioned eosinophils on biopsy (21),
whereas all except three EF cases showed eosinophils
on biopsy (22–24). Lastly, although peripheral eosin-
ophil count has been reported to be a surrogatemarker
for disease activity in EF, it has never been reported in
DPM. The robust response of this patient’s peripheral
eosinophilia to steroids is also a classic feature of EF.
The presence of steroid-responsive peripheral eosino-
philia as a diseasemarker also supports our contention
that EF and DPM may be on a continuum of disease
with similar pathophysiology, although it is important
to remember that DPM is rare, with only a few case
reports in the literature, and that DPMmay have some
features that overlap with EF that may not have been
previously reported. This child may not represent an
overlap of two diseases but rathermay be presenting as
DPM with novel features of EF. In spite of treatment
with high-dose steroids, various immunosuppressive
therapies, and autologous stem cell transplantation,
the patient’s disease has recurred, and he is currently
being treated with abatacept and steroids (Table 1).
Our patient presented with clinical and histopath-
ologic features of two subtypes of deep morphea: EF
and DPM. The simultaneous presentation indicates
that EF and DPM are closely related and may be
disease entities that fall along a continuum that
includes other forms of localized scleroderma, a
concept that is not currently recognized in currently
published classiﬁcation systems for localized juvenile
scleroderma. It is hoped that further understanding of
the pathogenesis of scleroderma and the complex
interplay of these various damaging processes will
change the current organ-based approach to more
eﬀective targeted therapy.
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